

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Review Proposal Project

#### Technology Appraisal guidance no. 164; Febuxostat for the management of hyperuricaemia in people with gout

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Febuxostat (Menarini Pharma)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Afiya Trust</li> <li>• Arthritic Association</li> <li>• Arthritis and Musculoskeletal Alliance (ARMA)</li> <li>• Arthritis Care</li> <li>• Black Health Agency</li> <li>• British Kidney Patient Association</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Kidney Alliance</li> <li>• Kidney Research UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Kidney Federation</li> <li>• National Rheumatoid Arthritis Society</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• UK Gout Society</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Renal Industries</li> <li>• Association of Renal Technologists</li> <li>• British Association for Services to the Elderly</li> <li>• British Dietetic Association</li> <li>• British Geriatrics Society</li> <li>• British Health Professionals in</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• AAH Pharmaceuticals (Allopurinol)</li> <li>• Accord Healthcare (Allopurinol)</li> <li>• Actavis (Allopurinol)</li> <li>• Almus Pharmaceuticals (Allopurinol)</li> <li>• Arrow Generics (Allopurinol)</li> <li>• Aspen (Allopurinol)</li> <li>• Barts and the London NHS Trust (Benzbromarone, Probenecid)</li> <li>• Bristol Laboratories (Allopurinol)</li> <li>• Burton Hospitals NHS Trust (Benzbromarone, Probenecid)</li> <li>• Calderdale and Huddersfield NHS Foundation Trust (Benzbromarone, Probenecid)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<p>Rheumatology</p> <ul style="list-style-type: none"> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Orthopaedic Association</li> <li>• British Pain Society</li> <li>• British Renal Society</li> <li>• British Society for Rheumatology</li> <li>• Chartered Society of Physiotherapy</li> <li>• College of Occupational Therapists</li> <li>• Physiotherapy Pain Association</li> <li>• Primary Care Rheumatology Society</li> <li>• Renal Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for DGH Nephrologists</li> <li>• Society for Endocrinology</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Calderdale</li> <li>• NHS Cambridgeshire</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Colchester Hospital University NHS Foundation Trust (Benzbromarone, Probenecid)</li> <li>• Co-Pharma (Allopurinol)</li> <li>• Dowelhurst (Allopurinol)</li> <li>• East Sussex Hospitals NHS Trust (Benzbromarone, Probenecid)</li> <li>• GlaxoSmithKline(Allopurinol)</li> <li>• Guy's and St. Thomas' NHS Foundation Trust (Benzbromarone, Probenecid )</li> <li>• Ipswich Hospital NHS Trust Benzbromarone, Probenecid)</li> <li>• Kent Pharmaceuticals (Allopurinol)</li> <li>• Moorfields Pharmaceuticals (Benzbromarone, Probenecid)</li> <li>• Newcastle upon Tyne Hospitals NHS Foundation Trust (Benzbromarone, Probenecid)</li> <li>• North West London Hospitals NHS Trust (Benzbromarone, Probenecid)</li> <li>• Nottingham University Hospitals NHS Trust (Benzbromarone, Probenecid)</li> <li>• Portsmouth Hospitals NHS Trust (Benzbromarone, Probenecid)</li> <li>• Preston Pharmaceuticals (Benzbromarone, Probenecid)</li> <li>• Ranbaxy (Allopurinol)</li> <li>• Royal Free Hampstead NHS Trust (Benzbromarone, Probenecid)</li> <li>• Sandoz (Allopurinol)</li> <li>• St George's Healthcare NHS Trust (Benzbromarone, Probenecid)</li> <li>• Stockport Pharmaceuticals (Benzbromarone, Probenecid)</li> <li>• Teva (Allopurinol)</li> <li>• Torbay PMU (Benzbromarone, Probenecid)</li> <li>• University College Hospital NHS Foundation Trust (Benzbromarone, Probenecid)</li> <li>• University Hospital of North Staffordshire NHS Trust Benzbromarone, Probenecid)</li> <li>• Wockhardt (Allopurinol)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="805 340 1177 376"><u>Relevant research groups</u></p> <ul data-bbox="805 380 1425 645" style="list-style-type: none"> <li>• Arthritis Research UK</li> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane Musculoskeletal Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p data-bbox="805 685 1082 721"><u>Assessment Group</u></p> <ul data-bbox="805 725 1393 869" style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p data-bbox="805 909 1281 945"><u>Associated Public Health Groups</u></p> <ul data-bbox="805 949 914 985" style="list-style-type: none"> <li>• Tbc</li> </ul> <p data-bbox="805 1025 1225 1061"><u>Associated Guideline Groups</u></p> <ul data-bbox="805 1066 914 1102" style="list-style-type: none"> <li>• Tbc</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.